<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01177904</url>
  </required_header>
  <id_info>
    <org_study_id>MAD-GK-01-2009-02</org_study_id>
    <nct_id>NCT01177904</nct_id>
  </id_info>
  <brief_title>Early Progesterone Cessation After in Vitro Fertilization</brief_title>
  <official_title>Early Progesterone Cessation After in Vitro Fertilization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Valenciano de Infertilidad, IVI VALENCIA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Valenciano de Infertilidad, IVI VALENCIA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There seems to be a general consensus on the supplementation of progesterone (P4) for luteal&#xD;
      phase support (LPS) to all women after in vitro fertilization (IVF) treatment. However, there&#xD;
      is no agreement about the precise duration of LPS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study is to investigate the effect of early cessation of progesterone&#xD;
      for LPS after IVF treatment on the pregnancy outcome, with special interest in determining&#xD;
      the miscarriage rate and episodes of bleeding between the date of the first ultrasound (US)&#xD;
      and up to 12 weeks of gestation.&#xD;
&#xD;
      Patients start to receive 200 mg twice a day of P4 on the day after oocyte retrieval.&#xD;
&#xD;
      All patients which show a gestational sac in their uterus in the first US are included in&#xD;
      this study and randomized.&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
        1. Patients who underwent ovarian stimulation using GnRH analogues,&#xD;
&#xD;
        2. Fresh embryo transfer,&#xD;
&#xD;
        3. LPS by vaginal micronized P4,&#xD;
&#xD;
        4. Clinical pregnancy demonstrated by US and&#xD;
&#xD;
        5. Informed consent signed.&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
      Patients who had bleeding episodes before their first US because they are likely to continue&#xD;
      P4 therapy without medical indication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progesterone</measure>
    <time_frame>june 2009</time_frame>
    <description>Our predictions are similar to those seen in previous studies:&#xD;
No significant change in the miscarriage rate.&#xD;
There may be a higher percentage of bleeding episodes in patients who stop LPS earlier, but it does not seem to have an impact.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>All Patients Which Show a Gestational Sac in Their Uterus in the First US Are Included in This Study and Randomized.</condition>
  <arm_group>
    <arm_group_label>Progesterone 5 Weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study group stop receiving P4 on the day of their first US at 5 weeks pregnancy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group : P4 8 weeks</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Progesterone will be given until 8 weeks of pregnancy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cease progsterone at 5</intervention_name>
    <description>Cease administration of progsterone at first US at 5 weeks</description>
    <arm_group_label>Progesterone 5 Weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control group: progesterone 8</intervention_name>
    <description>Control group: progesterone until 8 weeks of pregnancy</description>
    <arm_group_label>Control Group : P4 8 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who underwent ovarian stimulation using GnRH analogues,&#xD;
&#xD;
          2. Fresh embryo transfer,&#xD;
&#xD;
          3. LPS by vaginal micronized P4,&#xD;
&#xD;
          4. Clinical pregnancy demonstrated by US and&#xD;
&#xD;
          5. Informed consent signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who had bleeding episodes before their first US because they are likely to&#xD;
        continue P4 therapy without medical indication.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan A Garcia-Velasco, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>IVI Madrid</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IVI-Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>August 5, 2010</study_first_submitted>
  <study_first_submitted_qc>August 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2010</study_first_posted>
  <last_update_submitted>March 16, 2011</last_update_submitted>
  <last_update_submitted_qc>March 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Early progesterone cessation after in vitro fertilization</name_title>
    <organization>IVI Madrid</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 3, 2018</submitted>
    <returned>November 8, 2018</returned>
    <submitted>August 12, 2020</submitted>
    <returned>August 25, 2020</returned>
    <submitted>December 28, 2020</submitted>
    <returned>January 19, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

